Jun. 16 at 2:41 PM
$IXHL Incannex must resolve its compliance issues first.
That has a direct influence on its ability to raise capital, attract institutional investors, and execute its future plans.
So from the market’s view — you can’t celebrate future trial success if you’re at risk of being delisted.
Funds, traders, and market makers know this, and instead of skyrocketing on good trial news or warrant cancellations, the price might stay weak or range-bound while these structural issues are addressed first.
It’s a reflection of the market pricing in the Company’s operational and listing priorities first and trial data afterwards.
Once these uncertainties resolve, it should clear a path for momentum to accelerate, provided the trial results and corporate moves align positively.
